Saranas Invited to Present at CRT18 in Washington, DC

Published: Mar 02, 2018

HOUSTON--(BUSINESS WIRE)-- Saranas, a medical device company with a new technology for real-time detection and monitoring of internal bleeding during endovascular procedures, has been invited to present at the 21st Cardiovascular Research Technologies (CRT18) annual conference, March 6, 2018, in Washington, DC. Saranas was chosen to participate in the conference’s Cardiovascular Innovations session. The company’s Early Bird™ Bleed Monitoring System is nearing the end of final product testing, and the company expects to file a De Novo submission to the FDA in 2018.

“We are very honored to be chosen to present at this prestigious conference, especially from a highly competitive field,” President and CEO Zaffer Syed said. “It is our belief that our Early Bird Bleed Monitoring System can have an important impact on healthcare costs and reduce the risk of death in patients undergoing endovascular procedures. Presenting at CRT18 gives us the opportunity to discuss how the Early Bird can be integrated into clinical practice.’’

The Early Bird Bleed Monitoring System includes a vascular access sheath embedded with sensors that are designed to detect and monitor bleeding from a blood vessel accidentally ruptured during endovascular procedures, such as a transcatheter aortic valve implantation (TAVI), large bore hemodynamic support device placement, or other complex cardiovascular interventions, where the femoral artery or vein is used to obtain vascular access. The technology was invented at the Texas Heart Institute.

About Saranas

Saranas is a privately held Houston-based medical device company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company’s patented bleed monitoring system for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs. For more information, visit

Back to news